Results 171 to 180 of about 1,459,292 (318)

SGLT2i use and fracture risk compared with DPP4i in patients with T2DM

Journal of Diabetes Investigation, EarlyView.
ABSTRACT Introduction The association between sodium‐glucose cotransporter‐2 inhibitor (SGLT2i) use and fracture risk remains inconclusive. Most previous studies have focused on treatment‐naïve patients, despite many patients in routine clinical practice initiating SGLT2i therapy after prior dipeptidyl peptidase‐4 inhibitor (DPP4i) use.
Sung‐Yen Lin, Shih‐Hao Huang, Ching‐Han Chiang, Cheng‐Jung Ho, Chung‐Hwan Chen, Li‐Nien Chien   +5 more
wiley   +1 more source

Complex Drug Interactions of HIV Protease Inhibitors 1: Inactivation, Induction, and Inhibition of Cytochrome P450 3A by Ritonavir or Nelfinavir

Drug Metabolism And Disposition, 2011
B. Kirby, A. Collier, E. Kharasch, D. Whittington, K. Thummel, J. Unadkat   +5 more
semanticscholar   +1 more source

European Consortium for Lipodystrophies consensus definition and classification framework for monogenic lipodystrophy

Journal of Internal Medicine, EarlyView.
Abstract Lipodystrophy comprises a heterogeneous group of disorders characterized by reduced adipose tissue often associated with severe metabolic complications. Lipodystrophy may be genetic, acquired, or secondary to medical therapies initiated for other conditions.
Robert K. Semple, Martin Wabitsch, Baris Akinci, Saif Alyaarubi, Marjoleine F. Broekema, Rebecca J. Brown, Giovanni Ceccarini, Carolina Cecchetti, Solaf M. Elsayed, Antía Fernández‐Pombo, Alessandra Gambineri, Ingrid M. Jazet, Lotte Kleinendorst, Konstanze Miehle, Elif A. Oral, Flavia Prodam, Ferruccio Santini, David B. Savage, Nadia Shaukat Ali, Ekaterina Sorkina, Magdalena Szopa, Marie‐Christine Vantyghem, Camille Vatier, Corinne Vigouroux, Julia von Schnurbein, David Araújo‐Vilar   +25 more
wiley   +1 more source

Advancements in development of novel class of HIV protease inhibitors. [PDF]

Ann Med
Gu WG, Yin GZ, Zhang YP.
europepmc   +1 more source

Interaction of HIV protease inhibitors with OATP1B1, 1B3, and 2B1

Xenobiotica; the fate of foreign compounds in biological systems, 2010
P. Annaert, Zhi-Wei Ye, B. Stieger, P. Augustijns   +3 more
semanticscholar   +1 more source

Inflammatory and Immunological Basis of Periodontal Diseases

Journal of Periodontal Research, EarlyView.
The periodontal lesion emerges as an evolving immunological battlefield, where host–microbiome interactions, dysregulated immune responses, fragile resolution mechanisms, and inflammophilic dysbiosis converge to shift the balance from homeostasis to unrestrained tissue destruction.
Giacomo Baima, Marion Arce, Mario Romandini, Thomas Van Dyke   +3 more
wiley   +1 more source

Repurposing HIV Protease Inhibitors against West Nile Virus: Insights from Molecular Docking and Molecular Dynamics Simulations. [PDF]

ACS Phys Chem Au
Dos Santos RD, Colherinhas G, Cardoso WB.   +2 more
europepmc   +1 more source

Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs

AIDS (London), 2002
M. T. Huisman, J. Smit, K. Crommentuyn, N. Zelcer, H. Wiltshire, J. Beijnen, A. Schinkel   +6 more
semanticscholar   +1 more source

Viruses, Periodontitis, and Systemic Diseases

Journal of Periodontal Research, EarlyView.
This narrative review aimed to summarize current evidence on the viral involvement in periodontitis and its relevance for systemic diseases. The oral cavity acts as an active viral reservoir and dissemination platform, where virus–microbiome interactions may promote dysbiosis, periodontitis progression, and systemic inflammatory effects, while the ...
Kim Natalie Solte, Yvonne L. Hernandez‐Kapila, Henrik Dommisch   +2 more
wiley   +1 more source

Recent Advances in Heterocyclic HIV Protease Inhibitors. [PDF]

Int J Mol Sci
Funicello M, Chiummiento L, Santarsiere A, Poggio F, Lupattelli P.   +4 more
europepmc   +1 more source